NCT00550303已完成1 期
An Open-Label, Single-Dose, Non-Randomized, 4-Period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 28 人开始时间: 2007年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
- 主要终点
- Bioavailability
研究概览
简要总结
The primary purpose is to determine bioavailability of Bazedoxifene/conjugated estrogen formulations for future testing purposes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy, post menopausal women ages 45 to 70
排除标准
- •Male subjects
结局指标
主要结局
Bioavailability
次要结局
- Safety & tolerability
研究者
相似试验
已完成
1 期
Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal WomenMenopauseNCT00396799Wyeth is now a wholly owned subsidiary of Pfizer
已完成
1 期
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal WomenMenopauseNCT00464789Wyeth is now a wholly owned subsidiary of Pfizer
已完成
1 期
Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral SolutionPostmenopauseNCT00367536Wyeth is now a wholly owned subsidiary of Pfizer24
已完成
1 期
Study Evaluating Bazedoxifene/CE in Postmenopausal WomenPostmenopauseNCT00550433Wyeth is now a wholly owned subsidiary of Pfizer
已完成
3 期
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With MenopauseVaginal AtrophyNCT00238732Wyeth is now a wholly owned subsidiary of Pfizer650